Axis

Follow the day’s news liveGet our breaking news email, free app or daily news podcastGood morning all and thanks for being with us. Graham Readfearn here.First up, we will have news in a few minutes that NSW has recorded its first confirmed case of the deadly H5N1 bird flu in a giant petrel found north of Newcastle at Hawks Nest. Continue reading...

• Several high-profile stocks, including HDFC Bank, Axis Bank, YES Bank, and Afcons Infra, are expected to be in the spotlight on Tuesday, June 30. • Other companies likely to see increased market activity include RITES, Concor, SW Solar, KEC International, and SJVN. • These stocks are being monitored by investors as key drivers of market sentiment and trading volume for the day.

• Several major Indian financial stocks, including HDFC Bank, Axis Bank, SBI, and Yes Bank, are highlighted as key securities to watch today. • Coforge Ltd. is in focus following the appointment of Anup Nair as the company's new Chief AI Commercial Officer. • Corporate updates include the resignation of CFO Tarun Jaitly from Juniper Hotels and NLC India's issuance of commercial papers totaling Rs 400 crore on June 29, 2026.

• France, Germany, Italy, and 14 other European nations have signed a joint declaration to coordinate the testing of autonomous vehicles across international borders. • The agreement includes a total of 17 countries, including Belgium, Poland, Sweden, and the Netherlands, aiming to standardize the deployment of robotaxis. • This collaboration matters as it removes fragmented national barriers, potentially accelerating the adoption and scaling of self-driving technology throughout the EU.

• The FDA has approved the oral antiviral ensitrelvir (Xocova), developed by Shionogi & Co, Ltd, for post-exposure prophylaxis (PEP) of COVID-19. • The treatment is authorized for use in adults and adolescents aged 12 years and older to prevent symptomatic SARS-CoV-2 infection. • Approval was based on the SCORPIO-PEP phase 3 trial, which demonstrated the drug's safety and efficacy in household contacts of symptomatic patients.

• The FDA has approved the oral medication ensitrelvir for use as post-exposure prophylaxis (PEP) to prevent the onset of COVID-19 symptoms. • Approval follows phase 3 clinical trial data conducted between February 10 and July 10, 2022, across 92 sites in Japan, Vietnam, and South Korea, demonstrating efficacy against Omicron variants. • This development is significant as it provides a preventative option for individuals exposed to the virus in high-risk environments, including nursing homes, acute care facilities, and during travel.

Distressed riders who were stranded for hours say Apollo Go customer service agents offered ‘useless platitudes’A “system malfunction” has caused several self-driving robotaxis to stall in the middle of the road in China, police have confirmed, after distressed riders were stranded for hours.Local authorities in the central Chinese city of Wuhan said they began receiving calls “one after another” on Tuesday night from riders reporting that autonomous vehicles operated by the Chinese internet company Baidu had frozen. Continue reading...